NCT Heidelberg

NCT in brief

The NCT Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), the Heidelberg University Hospital and the German Cancer Aid. As Germany's first Comprehensive Cancer Center and Oncological Center of Excellence, the NCT combines excellence in research with interdisciplinary patient care under one roof.

The NCT acts as a central portal for all cancer patients of the Heidelberg University Hospital and is the clinical platform for translational projects and studies of the DKFZ.

Since 2015, a second site for the NCT beside Heidelberg has been under development in Dresden. The NCT Dresden is a joint venture by the German Cancer Research Center in Heidelberg, the University Hospital Carl Gustav Carus, the Medical Faculty of the TU Dresden and the Helmholtz Center Dresden-Rossendorf (HZDR).

Aim

We want to translate promising concepts from cancer research into patient care and cancer prevention, in order to stimulate studies and to develop new treatment and prevention strategies. The aim is to develop an individualized cancer medicine with targeted therapies for each individual patient.

History

2004: Launch and start of clinical operation
2005: Start of the first Tumor board
2006: First time awarded Oncological Center of Excellence by German Cancer Aid.
2006: Launch NCT Cancer Registry
2006: Launch NCT Trial Center
2009: Launch NCT Tissue Bank
2010: Move to the new NCT building
2012: For the first time awarded as “Selbsthilfefreundliches Krankenhaus” (“patient-oriented hospital”)
2013: Project launch NCT DataThereHouse
2015: Start build-up NCT partner site in Dresden; Start of a new funding program with federal funds to strengthen specific cancer research programs (NCT 3.0)
2016: For the third time awarded as “Selbsthilfefreundliches Krankenhaus” (“patient-oriented hospital”)

Patient care

  • Central portal for all cancer patients of the Heidelberg University Hospital
  • >20 % patients come from a radius of over 100 km
  • >60,000 patient visits per year during consultation
  • >20,000 systemic therapies per year
  • 15,000 patient visits for an initial appointment
  • 60 outpatient treatment spaces
  • Specialized oncological advice and information services, and self-help
Patient care

Clinical Trials

  • Currently around 500 oncological clinical studies and Investigator Initiated Trials (IITs)
  • >40% of all NCT patients are involved in clinical studies

Research

Research

Center-wide program for precision oncology with the aim of providing individual cancer medicine in areas such as genomics, proteomics, imaging, radiation therapy, immunology and prevention.

NCT translational research focuses in the areas of clinical discovery, molecular diagnostics, immunotherapy, integrative radiation oncology, cancer prevention, early detection and outcome.

As part of the expansion concept NCT 3.0 the following areas in Heidelberg will be extended and strengthened

  • Molecular stratification
  • Immunotherapy
  • Radio-oncology
  • Cancer screening, prevention and progression studies
  • Neurooncology, tumors of the gastrointestinal tracts and pediatric tumors
  • Molecular pathology
  • Oncological imaging

Quality

  • Evidence-based guidelines for diagnostics, therapy and post-therapy
  • >20 interdisciplinary tumor boards (daily)
  • Central units: NCT Cancer Registry, NCT Trial Center, NCT Tissue and Biobank

Staff

> 500 scientists, physicians and qualified scientific, clinical and administrative staff

Directorate

  • Consists of 14 directors»
  • Is composed of 7 representatives of each, the German Cancer Research Centre (DKFZ) and the Heidelberg University Hospital.
  • Managing Directors: Prof. Dr. Dirk Jäger, Prof. Dr. Stefan Fröhling (in ch.)
  • Deputy Managing Directors: Prof. Dr. Dr. Jürgen Debus, Prof. Dr. Peter Lichter